Company intelligence / Profile preview

AccurKardia

New York City, New York, United States

Ownership: Private
Employees: ~50
Development stage: Other

Overview

AccurKardia’s AccurECG™ platform is commercially available as an FDA-cleared SaMD for automated ECG interpretation. AK+ Guard™ and AK-AVS™ are investigational with FDA Breakthrough Device Designations; clinical studies and regulatory clearance for broader use are pending.

Therapeutic areas: NephrologyCardiovascular
Modalities: DeviceSoftware as a Medical Device (SaMD)Artificial Intelligence
Industry: Physiological Monitoring

Partnerships

HeartBeam (strategic device/software integration partnership)

Beyond the preview

Go deeper on AccurKardia.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on AccurKardia.

Explore the full profile